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Over the last few decades, the incidence of invasive candidal infections in neonatal intensive care units has increased
dramatically. Various complications, such as arthritis, endocarditis, meningitis, and endophthalmitis, have been
reviewed. We present the case of a premature infant with systemic candidemia. Arthritis was discovered 6 months
after completion of amphotericin B therapy, and was successfully treated with oral fluconazole for 6 weeks. We
conclude that long-term follow-up is particularly important in patients with treated candidemia. To prevent complications,
prolonged treatment with high-dose amphotericin B is suggested for systemic fungal infection, and oral fluconazole
is an effective alternative for candidal arthritis. [J Chin Med Assoc 2005;68(4):191–194]
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Introduction
Over the last few decades, the incidence of invasive can-
didal infections in neonatal intensive care units has
increased dramatically.1–3 This may be due to the early
use of peripherally inserted central venous catheters,
prolonged use of antibiotics, hyperalimentation, gas-
trointestinal defects, corticosteroid use, surgery, and
skin trauma. Various complications of systemic fun-
gal infection have been reviewed, such as arthritis, en-
docarditis, meningitis, and endophthalmitis.1,3 How-
ever, some reports showed that candidal arthritis
may develop several months after the completion of
systemic antifungal therapy.4,5 We present the case
of a premature infant with systemic candidemia and
arthritis 6 months after completion of treatment with
amphotericin B. The arthritis was successfully treated
with oral fluconazole for 6 weeks.
Case Report
A male infant with a gestational age of 29 weeks and
birth bodyweight of 1,104 g was born spontaneously
to a gravida 3 para 3 mother. The maternal history
included gestational diabetes mellitus, and 2 doses of
intramuscular dexamethasone before delivery. Apgar
scores were 5 and 6 at 1 and 5 minutes, respectively.
Physical examination was essentially normal, except
mild grunting and subcostal retraction at birth.
After transferring to our neonatal intensive care unit,
the patient was intubated with mechanical ventilation
because of respiratory distress and cyanosis. A course
of bovine surfactant (beractant [Survanta®; Abbott
Laboratories Inc, Columbus, OH, USA]) was given
under the impression of respiratory distress syn-
drome, and umbilical catheters were inserted for
fluid supply and laboratory monitoring.
On the day of admission, arterial blood-gas and
other parameters were as follows: PaCO2 46.4 mmHg;
PaO2 122 mmHg; pH 7.29; bicarbonate 21.9 mmol/L;
and base excess –4.6 mmol/L. A complete blood cell
count revealed the following values: white blood cells
5,900/+L (neutrophils 34%, lymphocytes 60%, mono-
cytes 2%, and normoblasts 2%); hemoglobin 15.3 g/dL;
and platelets 34,400/+L. Blood biochemistry re-
vealed sodium 132 mmol/L, potassium 5 mmol/L,
blood urea nitrogen 7 mg/dL, creatinine 0.5 mg/dL,
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C-reactive protein (CRP) 0.49 mg/dL, alanine ami-
notransferase 19 IU/L, and aspartate aminotrans-
ferase 78 IU/L. A central venous catheter was in-
serted peripherally in the right antecubital fossa for
parenteral nutrition on the patient’s third day of life.
At birth, septic work-up was performed, and
intravenous ampicillin and gentamicin were given.
Bacterial cultures were all negative. However, the
patient’s condition deteriorated on the seventh day
of life. Cultures were repeated, and antibiotics were
switched to oxacillin and ceftazidime. Candida
albicans was isolated from a peripheral blood culture
3 days later. The peripherally inserted central line was
removed, and amphotericin B was started at a dosage
of 0.25 mg/kg/day after a test dose. Cerebrospinal
fluid (CSF) culture was negative, but the tip of the
removed central venous catheter grew C. albicans.
The blood was clear of C. albicans after 2 weeks of
amphotericin B, and treatment was continued for
another 2 weeks; a total of 25.6 mg/kg was given.
Weekly blood cultures for fungus were taken 3 times,
but all proved to be negative. Further investigations
for disseminated fungal disease, including renal
ultrasound, ophthalmologic examination, and echo-
cardiogram, were all negative. The patient’s condi-
tion improved gradually, although complications
of prematurity (intraventricular hemorrhage with
post-hemorrhagic hydrocephalus, and patent ductus
arteriosus) developed later. After the episode of
systemic candidiasis, postnatal corticosteroids were
not used, and a central venous line was not re-
inserted peripherally.
The patient was re-admitted at age 6 months. His
vital signs were normal, and bodyweight gain was
acceptable. Unfortunately, a swollen left knee joint
with erythema and tenderness was discovered inci-
dentally. There was no history of a wound or trauma.
A series of bone scans and long-bone X-rays were
negative. However, an inflammatory process was
found over the left knee joint during a magnetic
resonance imaging study (Figure 1). The peripheral
leukocyte count was 16,500/+L (neutrophils 61%,
lymphocytes 25%, monocytes 7%, and eosinophils
6%), hemoglobin concentration was 8.2 g/dL, plate-
let count was 101,000/+L, and CRP level was 2.14
mg/dL. Vancomycin (45 mg/kg/day) was given ini-
tially because coagulase-negative Staphylococcus au-
reus was isolated from the left knee joint aspirate.
Signs of arthritis did not improve after 7 days of
treatment, and the patient became febrile, with a
temperature up to 38$C. The left knee joint was aspi-
rated again, and 0.2 mL of whitish fluid was obtained
for culture; C. albicans was apparent 3 days later.
CSF and blood cultures were all sterile. Intravenous
amphotericin B was administered again, but because
of difficult vascular access, treatment was switched to
oral fluconazole (8 mg/kg/day) 2 days later. The
fever subsided gradually, and the erythematous
appearance of the left knee joint improved during the
following 2 weeks. Eight days after fluconazole therapy,
synovial fluid from the left knee joint was clear of
C. albicans. The baby was discharged at that time, but
the left knee joint was still mildly swollen, with some
limitation of movement. Oral fluconazole therapy was
continued for a total of 6 weeks. Liver function tests
were normal. The baby was followed-up at age 1 year,
and all the joints, including the left knee, were freely
movable without any signs of inflammation.
Discussion
Fungal sepsis occurs in as many as 10% of low-birth-
weight infants.6 Most cases are due to Candida spp.,
particularly C. albicans, C. tropicalis, C. parapsilosis,
C. lusitaniae and C. glabrata. C. albicans is the lead-
ing cause of neonatal fungal sepsis, but non-albicans
Candida spp. have become more frequent causes.7
Risk factors for late-onset systemic candidiasis in-
clude prematurity, low birthweight, mechanical ven-
tilation, the use of broad-spectrum antibiotics, cor-
ticosteroid therapy, central vascular catheters, par-
enteral hyperalimentation, intralipid infusion, pro-
longed endotracheal intubation, necrotizing entero-
colitis, and immunologic immaturity.8 The clinical
manifestations of systemic candidiasis vary and are
indistinguishable from those of systemic infections
Figure 1. Cross-sectional, T2-weighted, magnetic resonance
imaging scan showing fluid accumulation in the left-knee synovial
cavity (arrow).
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caused by other pathogens. Nonetheless, fungal in-
fections should be considered in patients who have
been hospitalized for a prolonged period with paren-
teral nutrition or broad-spectrum antibiotic therapy.
Intravenous amphotericin B (total dosage 25–35 mg/
kg) remains the standard treatment for candidal sepsis;
moreover, general consensus exists that the removal
of foreign bodies, including prostheses and catheters,
helps to clear candidal infection. The intravenous or
oral use of fluconazole for neonatal candidemia has
been suggested as an alternative to amphotericin B,9,10
but the safety and efficacy of fluconazole in this setting
requires further large-scale, multicenter trials.
Eighty-five percent of cases of pediatric fungal
arthritis occur in infants aged less than 6 months, as
do 70–80% of cases associated with osteomyelitis.11
Infection originates hematogenously and seeds either
into the synovium or metaphyseal vessels. About
2-thirds of patients with fungal arthritis initially have
fever and tender joint(s), but mild arthritic symptoms
may delay the diagnosis for months to years.12 Blood
cultures should be obtained from all infants with
suspicious infection. Diagnostic aspiration of the joint
should be attempted to isolate the pathogen, and
bone scintigraphy remains more sensitive than
plain radiography for early diagnosis.13 Intravenous
amphotericin B is the drug of choice for both candidal
arthritis and systemic fungal infection, although some
reports have shown that fluconazole is an effective
alternative for the treatment of fungal arthritis in
premature infants.14,15
This case is interesting because the left-knee arthritis
occurred 6 months after the completion of treatment
for systemic fungal infection. This highlights the
previous observation that the presentation of arthritis
may be delayed from several months to 1 year after the
treatment of neonatal candidiasis.4,5 However, the
pathogenesis remains unclear. Swanson et al5 suggested
that Candida spp. might be latent or indolent in the
joint or liver for a period of time by demonstrating the
same DNA-based typing of organisms from the initial
candidemia and subsequent arthritis. This implies
that, during the initial candidiasis, there is seeding of
infection into the joints that is suppressed, but not
eliminated, by amphotericin B. Thus, what is the opti-
mal duration and dosage of treatment in neonatal can-
didiasis? A previous study suggested that 7–14 days
of amphotericin B therapy after the last positive blood
culture may be adequate,16 and that a total dose of
25 mg/kg should be sufficient.17 However, candidal
arthritis occurred in our patient, even with the above
recommended duration and dosage of treatment. From
this observation and previous reports,4,5 we postulate
that the current strategy for managing neonatal
candidemia may be inadequate. Further research
regarding more aggressive amphotericin B treatment,
either alone or in combination-therapy regimens,
should now be considered. Although we cannot prove
that the 2 C. albicans specimens from blood and
subsequent synovial fluid in our patient were of the
same serotype, the possibility of asymptomatic can-
didal recolonization and transient fungemia exists;
this underscores the importance of follow-up in
neonates with candidemia.
In conclusion, systemic candidiasis has become
more common in neonates hospitalized for prolonged
periods. Although our current regimen of amphoter-
icin B can cure most cases, care should be taken to
evaluate fungal seeding to other parts of the body, es-
pecially the joints. From our experience in this case,
a more aggressive duration and dosage of amphoteri-
cin B should be considered for systemic candidiasis,
and fluconazole is an effective alternative for candidal
arthritis.
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